Latest Updates
-
Masik Kalashtami August 2026: Significance, Puja Timings, Rituals And Why Lord Kala Bhairava Is Worshipped -
Why AAFT University Is Emerging as a Preferred Destination for Journalism Education in India -
AAFT Noida Trains Journalism Students on MSTV and AAFT24x7 Before They Enter Real Newsrooms -
Can Doctors Really Operate On Unborn Babies? Baby Theo Is First UK Baby To Undergo Groundbreaking Womb Surgery -
Who Was D.Y. Patil? Former Bihar Governor And Education Pioneer Passes Away At 91 -
Aishwarya Rai's Unseen Cannes 2026 Look Surfaces: Inside Her Tony Ward Couture Gown With Over 7,000 Pearls -
Mangala Gauri Vrat 2026: Significance, Puja Samagri, Vrat Katha And Why The Number 16 Is Auspicious -
World Breastfeeding Week: Travelling While Breastfeeding — Tips For Flights, Road Trips And Public Places -
Ananya Panday's ₹1.48 Lakh Sapphire Blue Gown Is A Refreshing Take On Evening Glamour -
World Breastfeeding Week 2026: Worried About Low Milk Supply? Expert Explains Myths, Facts, When To Seek Help
Old Drug May Hold Promise Against Hepatitis C

Researchers from Stanford University say that an old drug may be effective against hepatitis C.
The research team say that their hunch is based on two significant discoveries in fight against hepatitis C:
A protein called NS4B is actively involved in binding some of the genetic material, or RNA, and thus allows the virus to duplicate.
An obsolete anti-itching drug clemizole hydrochloride could obstruct the protein, leading to a tenfold decrease in virus replication.
"We're excited about this and we're actively moving forward toward clinical trials," Nature magazine quoted Dr. Jeffrey Glenn, associate professor of gastroenterology and hepatology, as saying.
With the help of coin-sized microfluidic chips that minimizes tabletop biological experiments down to the tiny scale of nanoliters, the research team was able to screen more than 1,200 drug candidates and find clemizole in just two weeks.
Unlike other proteins, NS4B is difficult to purify in large quantities while retaining the protein's natural properties and functionality.
Stephen Quake, PhD, professor of bioengineering and the other senior author said that the paper marks the first time that microfluidic technology has been used to discover a specific drug.
While researching for the specific drug to target the protein, co author Doron Gerber, PhD, in bioengineering discovered18 drugs that substantially reduced NS4B binding to its target RNA.
However they focused on clemizole because it is already known to be safe in humans.
Glenn said, that clemizole could become an essential component in a new class of multidrug treatments for hepatitis C.
The study appears in online edition of the journal Nature Biotechnology.
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.



Click it and Unblock the Notifications